Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 462 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated Phase 4 Interventional Results available

PROUD Study - Preventing Opioid Use Disorders

NCT04766996
Conditions
Anesthesia, Opioid Use
Interventions
Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol
Behavioral · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Multiple Myeloma
Interventions
ACY-241, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
11
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 7 more
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Encinitas, California • West Hills, California • West Hollywood, California + 4 more
Conditions
Multiple Myeloma
Interventions
Oprozomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more
Not yet recruiting Phase 4 Interventional

Dose Dependent Steroid Injections

NCT07494136
Conditions
Lumbar Radiculopathy, Sciatica, Back Pain With Radiation
Interventions
Triamcinolone 10 Mg/mL Injectable Suspension, Triamcinolone 40 Mg/mL Injectable Suspension, Triamcinolone 80 Mg/mL Injectable Suspension, Dexamethasone 2 MG, Dexamethasone 4mg, Dexamethasone 8 MG
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Multiple Myeloma
Interventions
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Mobile, Alabama • Phoenix, Arizona • Sedona, Arizona + 23 more
Conditions
Multiple Myeloma
Interventions
Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Conditions
Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Interventions
Rovalpituzumab tesirine, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexamethasone in Total Knee Arthroplasty

NCT05018091
Conditions
Total Knee Arthroplasty
Interventions
Dexamethasone 4mg, Dexamethasone 8 Mg/mL Injectable Suspension, Dexamethasone 16mg
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
10
States / cities
Redwood City, California • San Francisco, California • Chicago, Illinois + 5 more
Conditions
Multiple Myeloma
Interventions
Magrolimab, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Palo Alto, California + 13 more
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Conditions
Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
Interventions
Erwinase, Vincristine, Dexamethasone, Doxorubicin, Cytarabine, Methotrexate, Triple Intrathecal Therapy, Dexrazoxane
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Dexamethasone, Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Palm Springs, California • Riverside, California • Glenwood Springs, Colorado + 26 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lung Cancer
Interventions
DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

NCT01102426
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Plitidepsin, Dexamethasone
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Jacksonville, Florida + 2 more
Conditions
Advanced Cancer
Interventions
PTC299, Docetaxel
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Neuromuscular Scoliosis, Adolescent Idiopathic Scoliosis
Interventions
Dexamethasone
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
9 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Completed Phase 4 Interventional Results available

Dexamethasone vs Ondansetron After Cesarean Delivery

NCT05692245
Conditions
Nausea and Vomiting, Postoperative, Cesarean Section Complications
Interventions
Ondansetron, Dexamethasone
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Leukemia
Interventions
Rituximab, Imatinib, Cyclophosphamide, Doxorubicin, Mesna, VSLI, Solu-Medrol, Methotrexate, Ara-C, G-CSF, Pegfilgrastim, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Results available

Muscle Relaxation for Pediatric Adenotonsillectomy

NCT06225466
Conditions
Tonsillectomy
Interventions
Rocuronium, Sugammadex, Anesthesia without neuromuscular blockade
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 12 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas